PHASE 2 KEYNOTE-667 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (Chl) AND SLOW EARLY RESPONSE (SER) TO FRONTLINE CHEMOTHERAPY (CHEMO). (October 2022) - Vinti, L.